NCT04972760View on ClinicalTrials.gov

Baricitinib in Patients With Relapsing or naïve Dermatomyositis

PHASE3RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Dermatomyositis
Interventions
DRUG

Baricitinib

Baricitinib, 4 mg/d, oral route for 24 weeks

DRUG

Placebo

Placebo, 4 mg/d, oral route for 24 weeks

Trial Locations (1)

75013

RECRUITING

Pitie-Salpêtrière hospital APHP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER